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Abstract  
 
Neuromuscular blocking agents are used in the 
operating room to allow safe intubation and prevent 
dangerous movement during surgery. Six patients 
scheduled for laparoscopic surgery were monitored 
throughout the operation. We then adjusted the 
pharmacodynamic model parameters to better fit 
individual patient responses. Adjusting the models as 
the patient began to recover provided significantly 
better prediction of recovery from rocuronium when 
adjusted at a train-of-four ratio of 0.3. When these 
predictions are displayed to an anesthesiologist, or an 
astronaut who may be less trained in anesthesia, they 
may help in determining if another bolus of 
rocuronium or a reversal agent should be 
administered, or when to expect spontaneous muscle 
activity for safe extubation. 
1. Introduction 
 
     Neuromuscular blocking agents are widely 
administered to patients during operations. On the 
space station, anesthesia may be used as emergency 
tratment for an astronaut, or animals may be put to 
sleep for biology experiments such as dissections or 
small implant surgeries. Astronauts come from all 
disciplines and are rarely trained in anesthesiology. An 
anesthesia display such as the one developed in our lab 
(Figure 1) could be extremely useful in such a 
situation1. Either the drugs given could be 
automatically tracked or the astronauts could enter the 
information by hand, stating what drug was given at 
what time. The anesthesia drug display could then 
calculate in real time what the predicted effects of the 
drug are on the animal or astronaut.  
 
 
Figure 1. Anesthesia Drug Display Prototype. The 
neuromuscular blockade portion is shown. The left 
section shows the effect site drug concentration and the 
right side shows the train-of-four count predicted 
effect. 
 
     The drug display shows the administration and 
effects of three different drugs: measuring sedation, 
pain, and muscle relaxation. The y-axes of the graphs 
show the drug concentration, and the x-axes are time. 
The vertical lines show a bolus of the drug, and then 
the solid line is the predicted drug effect site 
concentration (from the model). The dotted lines show 
what the drug levels will be in the near future, allowing 
time for the anesthesiologist to better think ahead and 
adjust medications if necessary. On the far right of the 
display, the predicted clinical effect is shown. 
 
     During surgery anesthesia may be used for sedation 
(rendering the patient unconscious and unaware of their 
surroundings), analgesia (pain), or for neuromuscular 
(NMB) blockade (muscle relaxation). The drug display 
shows this information in real time and will eventually 
adapt the model to specific during the surgery to reflect 
each patient’s needs and sensitivity to the medication. 
The plot on the left shows the drug concentrations 
predicted in the subject’s body, while the plot on the 
right shows the predicted effect of the patient to the 
drug given. In the case of muscle relaxants, a 
commonly used measure of effect called Train-of-four 
(TOF) count is displayed. 
 
     The purpose of relaxing a patient is to avoid 
unwanted muscular responses. One example of this is 
for intubation2. As the anesthesiologist places a tube 
down the patient’s trachea and connects it to a 
ventilator, the patient may have a gag reflex. Another 
possible reaction would be contractions in the abdomen 
due to a surgical stimulus2. The doctor does not want 
the abdomen to contract while he has sensitive surgical 
instruments (i.e. a knife) in the area. Muscle relaxants 
(neuromuscular blocking agents) suppress reactions 
like this allowing for easier care and management by 
healthcare professionals3. 
 
     Monitoring of neuromuscular blockade and its 
effects is most often accomplished with train of four 
stimulation and measurement. TOF measurement 
consists of four short current stimulations, which cause 
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the adductor pollicis (thumb and index finger) to twitch 
four times4. As the muscle relaxant takes effect, the 
patient response reduces to three twitches, then two, 
one, and finally zero. At zero twitches the 
neuromuscular blockade is in full effect and the patient 
is very relaxed, so that muscles should not respond to a 
given stimuli. At four twitch responses the TOF ratio is 
used. This is a measure of the strength of the fourth 
twitch response (T4) divided by the strength of the first 
twitch response (T1). Using this measure allows more 
fidelity in determining how close to normal a person is 
with respect to neuromuscular function. A ratio of 1 
means that neuromuscular function is normal and that 
four full twitch responses are present. The lower the 
ratio, the more relaxed a person is and the weaker their 
response to a given stimulus.  
 
     The models used to predict patient reactions to the 
drug can be split into two categories: pharmacokinetic 
and pharmacodynamic5. Pharmacokinetic models are 
those that predict the concentration of the drug in the 
bloodstream, and the pharmacodynamic models take 
this drug concentration and predict the effect on the 
patient. 
 
     The pharmacokinetic (PK) model used in this study 
is the Wierda three-compartment model. The three 
compartments consist of the bloodstream, muscular 
tissues, and fatty tissues. An additional, negligable 
compartment represents the effect site in the body. The 
model includes parameters that account for 
equilibration between these compartments. The drug 
display implimentation of the model is the same 
implementation as Stanpump, a well-known anesthesia 
modeling simulation6. The pharmacodynamic (PD) 
model used this study is Plaud’s model4. This model 
uses the Hill equation to calculate the TOF ratio 
response (from the effect site drug concentration, at the 
hand)4.  
2. Methods 
2.1 Experimental Setup 
 
     At the beginning of each case the NMT module was 
plugged into the Datex AS/3 monitor. A Toshiba 
Satellite Pro Pentium III laptop running Windows XP 
was connected to each device. The Datex monitor was 
connected directly through the serial port. Rugloop was 
used to collect all information from the Datex monitor. 
Drug boluses were given through the intravenous (IV) 
line. 
 
     During preparation for surgery in the operating 
room, the Datex Mechanosensor was placed on the 
patient’s thumb and index finger and taped in place 
(tape was applied between the thumb and index finger 
to prevent sensor movement during surgery, see Figure 
2). The sensor was placed on the most convenient arm. 
Preference was given to the arm without the IV (the 
sensor was placed on the right arm in most cases).  The 
arm was then wiped with an alcohol pad to remove oil 
from the skin and allow better electrode performance. 
A Smiths STS-400 disposable skin temperature sensor 
was placed on the palm and connected to the Datex 
monitor. As soon as the patient lost consciousness, the 
electrodes were placed on the wrist, above the ulnar 
nerve. Time permitting, small stimulations from the 
Microstim Plus were used to help locate the ulnar nerve 
at the arm and determine the optimal position for 
electrode placement. 
 
     The Datex monitor automatically set the 
supramaximal current by delivering single twitch 
stimulations starting at 40 mA, and then increasing 
current levels in 5 mA increments until the twitch 
response reached a maximum strength. Then the 
current was automatically increased 20% for 
supramaximal current. This maximum twitch response 
was the baseline value for T1 strength. In the cases that 
a maximum response was not found, the stimulator 
current was set to deliver 70 mA, and the twitch 
response was automatically set as the baseline T1 
strength. Train-of-four response was measured every 
20 seconds using a stimulation pulse duration of 100 
µsec. We recorded the times when recovery of 0.7 TOF 
ratio was reached. The sensor and electrodes were 
removed before the patient regained consciousness.  
 
 
Figure 2. Train of four stimulator and sensor. 
2.2 Data Analysis 
 
     Patient details are summarized in Table 1. Patient 
data was excluded from analysis due to the following 
criteria: the NMB agent succinylcholine was 
administered, data was visually noisy, or if TOF ratio 
did not recover to 0.7 before reversal. One patient was 
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excluded due to a communication problem with the 
computer and the equipment. A total of 6 patients (out 
of 20 total) met the inclusion criteria for TOF ratio 
analysis.  
 
Subject Age Weight Height Gender 
# (years) (kg) (cm)  
1 29 67.6 172 Male 
2 28 76.8 183 Male 
3 41 104.1 180 Male 
4 60 60 160 Female 
5 22 72.1 172 Male 
6 34 53.5 165 Female 
Mean 36 72 172 4 M / 2 F
St. Dev. 14 18 9  
Table 1. Subject details: age, weight, height, and gender 
of the subjects who met the inclusion criteria for TOF ratio 
analysis. 
 
     The data analysis focused on the recovery phase 
only of each patient’s neuromuscular function. Figure 3 
shows an example of how the data was clipped for this 
analysis. In order to focus on the recovery phase, the 
data set was clipped after the onset, or maximum 
effect, occurred. Data was also clipped before 
administration of reversal agent so that recovery results 
of only rocuronium were studied. In the cases where 
maintenance doses of rocuronium were delivered, the 
data was clipped before the maintenance dose was 
administered.  
 
 
Figure 3. The shaded regions of the figure show where 
the data was clipped. (Notice the sharp rise in response 
due to neostigmine administration near the end of the 
data set.) The unshaded region is the recovery portion 
of the data used for analysis. The dashed line 
represents the model predicted response. . The points 
highlighted as dots are the three points used to 
calculate a new EC50 value. The points highlighted 
with circles show which points were used to calculate a 
new γ value.  
2.2.1 Post Hoc determination of best-fit EC50 & 
γ  using Nonlinear Least Squares 
 
     A nonlinear least squares method was performed in 
MATLAB to find the best-fit pharmacodynamic 
parameters, EC50 and γ, which predict the effect (T1 
strength or TOF ratio) using the Hill equation, 
Equation 2. (Ceff was calculated using the Wierda PK 
model.) Effect was the TOF ratio, E0 was the effect 
with no drug present (TOF ratio = 1), and Emax was the 
mazimum effect possible (TOF = 0). 
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2.2.2 Calculation of patient specific EC50 & γ   
 
     When TOF ratio recovered to 0.2, a new EC50 was 
calculated using Equation 3, and Ceff from the Wierda 
PK model. The EC50 was calculated and averaged over 
three data points (the first minute above the recovery 
threshold). This averaging method was used to reduce 
the variability, as well as to reduce the influence of 
possible spikes in the data when calculating the new 
EC50 value, hopefully resulting in a more accurate 
prediction. 
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     Adjustment of γ was also explored. The new γ was 
calculated using a rearranged Hill equation, Equation 4. 
γ was calculated using the newly adjusted EC50 value at 
each point between recovery of 0.2-0.3 TOF ratio. The 
gammas calculated were averaged to find a new, 
patient specific γ. 
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3. Results 
3.1 Nonlinear Least Squares determination 
of best-fit PD Parameters, EC50 & γ 
 
     Table 2 shows the γ and EC50 parameter values for 
each subject, which provided the best fit to TOF ratio 
data when the Wierda PK model was used to calculate 
Ceff. 
 
Post hoc 
Nonlinear Least Squares 
Calculations of γ and EC50 
Subject EC50 γ 
1 510 3.9 
2 935 10.7 
3 565 6.1 
4 459 4.4 
5 603 5.2 
6 790 5.5 
Average 644 6.0 
Std. Dev. 182 2.4 
Table 2. Gamma and EC50 values which provide the 
best fit to TOF ratio data in each subject.  
3.2 Adjustment of PD Parameters 
 
     Tables 3-6 show TOF times to 0.7 recovery, 
measured and predicted (before and after model 
adjustments). The resulting time differences in 
estimating extubation (TOF = 0.7) are also shown. 
Table 3 shows these recovery times using the 
unadjusted, average population values for γ and EC50. 
The EC50 value was adjusted at recovery ratio of 0.2 in 
Table 4. Table 5 shows the results when γ was also 
adjusted, at a recovery ratio of 0.2-0.3. At TOF ratio 
recovery of 0.3, the EC50 was adjusted again and the 
results are shown in Table 6. Adjusting the EC50 value 
at 0.3 recovery results in a closer prediction of 
extubation time than the EC50 adjustment at 0.2 
recovery (2.5 rather than 3.5 minutes).  
 
Time to TOF Ratio Recovery of 0.7 (in minutes) 
(using average population EC50 and γ) 
Subject EC50 γ 
Measured 
Time 
Predicted 
Time Difference 
1 644 6 58.9 52.6 -6.3 
2 644 6 29.8 42.5 12.6 
3 644 6 64.3 56.3 -8.0 
4 644 6 59.5 45.5 -14.0 
5 644 6 53.3 50.3 -3.0 
6 644 6 55.3 61.3 6.0 
Average     8.3 
Std. Dev.     4.2 
Table 3. The time to recovery of 0.7 TOF ratio, in 
minutes, using the average population γ and EC50. The 
difference between the measured and predicted times 
are also shown. 
 
Time to TOF Ratio Recovery of 0.7 (in minutes) 
(with EC50 calculations) 
Subject
Adjusted 
EC50 γ 
Measured 
Time 
Predicted 
Time Difference
1 530 6 58.9 59.6 0.7 
2 875 6 29.8 32.9 3.0 
3 565 6 64.3 61.3 -3.0 
4 491 6 59.5 54.8 -4.7 
5 745 6 53.3 45.6 -7.7 
6 791 6 55.3 53.6 -1.7 
Average     3.5 
Std. Dev.     2.5 
Table 4. The time to recovery of 0.7 TOF ratio, in 
minutes, using the average population γ and EC50 
adjusted at recovery of 0.2 TOF ratio. The difference 
between the measured and predicted times are also 
shown. 
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Time to TOF Ratio Recovery of 0.7 (in minutes) 
(with EC50 and γ calculations) 
Subject 
Adjusted 
EC50 
Adjusted 
 γ 
Meas. 
Time 
Pred.
Time Difference
1 530 5.7 58.9 59.9 1.0 
2 875 6.5 29.8 32.5 2.7 
3 565 5.8 64.3 61.3 -3.0 
4 491 4.8 59.5 56.2 -3.3 
5 745 7.0 53.3 44.6 -8.7 
6 791 5.7 55.3 53.6 -1.7 
Average     3.4 
Std. 
Dev.     2.7 
Table 5. The time to recovery of 0.7 TOF ratio, in 
minutes, using γ calculated from 0.2-0.3 TOF ratio 
recovery, and EC50 adjusted at recovery of 0.2 TOF 
ratio. The difference between the measured and 
predicted times are also shown. 
 
Time to TOF Ratio Recovery of 0.7 (in minutes) 
(with EC50 and γ calculations) 
Subject 
Adjusted 
EC50 
Adjusted  
γ 
Meas. 
Time 
Pred.
Time Difference
1 546 5.7 58.9 57.6 -1.3 
2 910 6.5 29.8 31.3 1.5 
3 573 5.8 64.3 60.3 -4.0 
4 466 4.8 59.5 57.5 -2.0 
5 602 7.0 53.3 55.6 2.3 
6 825 5.7 55.3 50.9 -4.3 
Average     2.6 
Std. 
Dev.     1.3 
Table 6. The time to recovery of 0.7 TOF ratio, in 
minutes, using γ calculated from 0.2-0.3 TOF ratio 
recovery, and EC50 adjusted at recovery of 0.3 TOF 
ratio. The difference between the measured and 
predicted times are also shown. 
4. Discussion 
 
     Adjusting the EC50 and γ pharmacodynamic 
parameters at patient recovery of 0.2 and 0.3 resulted in 
more accurate predictions of recovery time using TOF 
ratio. Our results indicate that the prediction of time 
that the models produce will be accurate within an 
average of 3.5 minutes using TOF ratio. This is about a 
50% average improvement over using the population’s 
average pharmacodynamic parameters to predict 
recovery time. Without adjustments, the predictions 
would be within about 8.3 minutes. This patient-
specific prediction of recovery time may help the 
anesthesiologist better manage care of each patient, 
such as in determining when is necessary and effective 
to administer reversal and maintenance doses. The 
clinical significance of this is that the anesthesiologist 
can look into the future and have a quantitative 
prediction of the time left before a patient is expected 
to recover. It is also useful for situations where 
someone such as an astronaut less familiar with 
anesthesia may be required to administer drugs to a 
fellow astronaut or for animal experiments. This 
analysis leads to conclusion that an effective way to 
adjust the neuromuscular PD models reliably is to 
measure the TOF ratio during recovery (at 0.2) and use 
that information as feedback into the model by 
adjusting the parameters real-time. 
 
     The EC50 values have a fairly large variance 
(standard deviation of 162), which is consistent with 
other studies performed using rocuronium (Plaud’s 
standard deviation of 157). The variability of these 
EC50s were comparable to the variability in Plaud’s 
dataset, suggesting that the optimized EC50 values 
derived in this study are accurate. Variation for γ 
(standard deviation of 3.8) in this study is fairly high. 
An explanation for this variability is that there are a 
small number of patients. 
5. Limitations 
 
     One major limitation in this study was that it was an 
observational study. The primary effect was that there 
was only a small window of time in which to calibrate 
the stimulator and sensor, and reversal agent was often 
given before TOF rato recovery reached 0.7. The 
results of this study also may be limited to the patient 
population studied and the Datex mechanosensor used 
to collect the data. There were some problems with the 
sensor, in that the baseline calibration shifted during 
surgery in several cases so that the final T1 strength 
was up to four times above or below the original 
calibrated baseline value of 100%. In addition, reversal 
agent was administered in most cases. It is 
recommended that future studies allow the patient to 
recover without reversal agent for a more complete 
dataset. 
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6. Future Work 
 
     A future study is needed to explore the relationship 
between the T1 strength, TOF count, and TOF ratio. 
Adjusting the TOF count in real time could also be 
helpful to the anesthesiologists because they are more 
familiar with it, and TOF count is easier to observe 
than T1 strength or TOF ratio.  
 
     Simulations may be run with any PK-PD model 
combination to test that this method of adjusting EC50 
and γ is effective independent of the models used. For 
example, the Plaud, Wierda, and Szenorhadsky PK 
modes may be used to predict the TOF ratio and T1 
response. They may be used with Plaud’s or another 
PD model, whose EC50 and γ would then be adjusted 
during recovery. The difference in predicted recovery 
time could then be used to determine if the method was 
effective with each model combination. In addition, 
this method of adjusting the PD models during 
recovery to achieve more patient specific, accurate 
results, may be extended and tested with other drug 
models and effects helpful to anesthesiologists (i.e. 
BIS/sedation, analgesia). 
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